Objective To assess the effectiveness and safety of thalidomide for treating multiple myeloma in China.
Methods Randomized controlled trials (RCTs) of thalidomide for multiple myeloma were collected from CNKI (1979 to 2008), CBMdisc (1979 to 2008), and VIP (1989 to 2008) databases. Other relevant journals were also handsearched. The methodological quality of the included studies was evaluated, and data analyses were performed using the Cochrane Collaboration’s software RevMan 4.3.
Results A total of 9 RCTs involving 324 patients were included. As for the total effective rate and complete remission rate, significant differences were found between thalidomide + MP vs. MP alone (RR=1.34, 95%CI 1.05 to 1.70; RR=1.77, 95%CI 1.26 to 2.49) and thalidomide + VAD vs. VAD alone (RR=1.45, 95%CI 1.20 to 1.75; RR=1.73, 95%CI 1.25 to 2.39).
Conclusion According to the domestic evidence, treatment for multiple myeloma with thalidomide can improve the total effective rate and the complete remission rate. However, more high–quality, large-sample, randomized, double-blind, controlled trials are required.
Citation：
ZHU Ke,LIU Zhuogang,YANG Wei,JIANG Benchun. Effectiveness and Safety of Thalidomide for Treating Multiple Myeloma in China: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2009, 09(8): 899-903. doi: 10.7507/1672-2531.20090158
Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
张之南, 主编. 血液病诊断及疗效标准. 第2版. 北京: 科学出版社, 1998. 171-173.
|
| 2. |
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.
|
| 3. |
Higgins JPT, Thompson SG, Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11): 1539-1558.
|
| 4. |
路平, 路蓉, 王永志, 等. 沙利度胺联合MP方案治疗多发性骨髓瘤48例. 中国医师杂志, 2006, 10(8): 1439.
|
| 5. |
武贵存, 卞晓山, 魏长宏, 等. 沙利度胺联合VAD方案治疗多发性骨髓瘤的临床观察. 山东医药, 2008, 7(48): 58.
|
| 6. |
袁宇宁, 张星星, 朱绮文. 沙利度胺联合VAD方案治疗多发性骨髓瘤的临床研究. 临床血液学杂志, 2004, 4(17): 209-211.
|
| 7. |
王璇, 何海涛, 姜欣. 沙利度胺联合VAD方案治疗治疗难治性多发性骨髓瘤临床分析. 中国现代医学杂志, 2008, 3(18): 379-380.
|
| 8. |
陈莉莉, 王友群, 汪文华, 等. 沙利度胺联合化疗治疗多发性骨髓瘤的临床观察. 中国医院药学杂志, 2005, 8(25): 755-756.
|
| 9. |
洪莉. 沙利度胺联合VAD方案治疗治疗多发性骨髓瘤疗效观察. 中国实用医药, 2008, 5(3): 53-54.
|
| 10. |
晋红丽, 韩艳玲, 孙静, 等. 小剂量沙利度胺联合VAD方案治疗治疗多发性骨髓瘤的临床研究. 中国医药指南, 2007, 9(5): 27-28.
|
| 11. |
岑海燕, 陈钰. 反应停联合VAD方案治疗治疗多发性骨髓瘤的疗效. 中国肿瘤生物治疗杂志, 2006, 5(13): 384-386.
|
| 12. |
王璇, 尹颖, 张慧莹. 沙利度胺联合MP方案治疗多发性骨髓瘤临床观察. 中国误诊学杂志, 2007, 12(7): 2739.
|
| 13. |
Hicks LK, Haynes AE, Reece DE,et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev, 2008, 5(34): 442-452.
|
- 1. 张之南, 主编. 血液病诊断及疗效标准. 第2版. 北京: 科学出版社, 1998. 171-173.
- 2. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.
- 3. Higgins JPT, Thompson SG, Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11): 1539-1558.
- 4. 路平, 路蓉, 王永志, 等. 沙利度胺联合MP方案治疗多发性骨髓瘤48例. 中国医师杂志, 2006, 10(8): 1439.
- 5. 武贵存, 卞晓山, 魏长宏, 等. 沙利度胺联合VAD方案治疗多发性骨髓瘤的临床观察. 山东医药, 2008, 7(48): 58.
- 6. 袁宇宁, 张星星, 朱绮文. 沙利度胺联合VAD方案治疗多发性骨髓瘤的临床研究. 临床血液学杂志, 2004, 4(17): 209-211.
- 7. 王璇, 何海涛, 姜欣. 沙利度胺联合VAD方案治疗治疗难治性多发性骨髓瘤临床分析. 中国现代医学杂志, 2008, 3(18): 379-380.
- 8. 陈莉莉, 王友群, 汪文华, 等. 沙利度胺联合化疗治疗多发性骨髓瘤的临床观察. 中国医院药学杂志, 2005, 8(25): 755-756.
- 9. 洪莉. 沙利度胺联合VAD方案治疗治疗多发性骨髓瘤疗效观察. 中国实用医药, 2008, 5(3): 53-54.
- 10. 晋红丽, 韩艳玲, 孙静, 等. 小剂量沙利度胺联合VAD方案治疗治疗多发性骨髓瘤的临床研究. 中国医药指南, 2007, 9(5): 27-28.
- 11. 岑海燕, 陈钰. 反应停联合VAD方案治疗治疗多发性骨髓瘤的疗效. 中国肿瘤生物治疗杂志, 2006, 5(13): 384-386.
- 12. 王璇, 尹颖, 张慧莹. 沙利度胺联合MP方案治疗多发性骨髓瘤临床观察. 中国误诊学杂志, 2007, 12(7): 2739.
- 13. Hicks LK, Haynes AE, Reece DE,et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev, 2008, 5(34): 442-452.
